Casein Kinase II Inhibitor VIII

A cell-permeable thiazolamide compound that acts as a potent, reversible, and ATP-competitive inhibitor against casein kinase-2/CK2 (IC₅₀ = 32 and 46 nM against CK2α and CK2α′, respectively), as well as DYRK1B and FLt-3 (82% and 76% inhibition, respectively, at 30 nM), while diplaying reduced or little potency toward other targets in a 70-kinase panel selectivity profile study. Shown to effectively block the proliferation of a variety of cancer cells (IC₅₀ = 2.6, 1.6, and 2.4 µM, in A549, HCT116, and MCF-7 cultures, respectively).

Secondary Target
DYRK1B, Flt-3

Target IC₅₀: 32 and 46 nM for CK2&alpha

Cell permeable: yes

Primary Target
CK2

Reversible: yes

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Hou, Z., et al. 2012. J. Med. Chem.55, 2899.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)